Nicotine Rewired Your Brain First. Every Other Drug Just Followed the Same Path.

This is the Rize Newsroom Substance Spotlight for the week of June 27, 2026 — a focused look at nicotine and tobacco from a biology and treatment lens. Rotation: day 178, nicotine-tobacco.

---

Marcus had been off heroin for fourteen months when his counselor finally asked about the smoking. It wasn’t that anyone had forgotten — his chart listed it clearly, two packs a day, started at fifteen — it was that the program didn’t have a way to address it. The outpatient clinic was doing everything it was supposed to do for opioid use disorder: weekly check-ins, medication management, group sessions, urinalysis. Nobody had ever suggested that the thing Marcus was inhaling forty times a day was also a drug, also a disorder, also a target for treatment. He quit nicotine the same year he quit heroin, eventually, on his own, by accident almost — and he has said in published interviews that quitting smoking was harder.

He is not alone in that experience. Approximately 80 percent of people in SUD treatment also use tobacco, a number that has barely moved in decades. Only 42 percent of SUD treatment programs offer any tobacco cessation services. The field has managed to treat nicotine addiction and substance use disorder as if they occupied entirely separate clinical universes, even as the biology has been telling us for thirty years that the same brain systems power both.

Nicotine isn’t the afterthought of addiction. It is the original model.

---

What nicotine does to the brain — and why it matters for everything else

Nicotine is a natural compound that plants produce as an insecticide. It targets receptors in your nervous system called nicotinic acetylcholine receptors (nAChRs) — specialized docking sites designed to receive acetylcholine, the neurotransmitter your brain uses for attention, learning, and memory. Nicotine mimics acetylcholine well enough to activate these receptors directly, which is why a cigarette can sharpen focus momentarily and why withdrawal feels like a fog settling over your thinking.

The most addiction-relevant receptor subtype is called α4β2 — Greek letters naming the protein components of the receptor. This receptor is the primary target of nicotine’s most powerful action: triggering the release of dopamine in the nucleus accumbens, the brain’s reward center — the same reward pathway that responds to heroin, to methamphetamine, to alcohol. The dopamine spike tells the brain: do that again. With repeated exposure, the brain begins to adjust: it upregulates (builds more of) the α4β2 receptors to compensate for the constant stimulation. This is tolerance. And when nicotine stops arriving — when you try to quit — those extra receptors are sitting there waiting for stimulation that doesn’t come, producing what we experience as craving and the constellation of withdrawal symptoms: anxiety, irritability, difficulty concentrating, the overwhelming sense that something is wrong.

Varenicline (Chantix), the most effective smoking cessation medication currently approved, is a partial agonist of α4β2 — it partially activates the receptor, providing enough dopamine modulation to blunt withdrawal while blocking nicotine from producing its full effect. Cytisinicline, a plant-derived compound from the golden rain tree used in Eastern European countries for decades as an affordable alternative to pharmaceutical cessation aids, works through the same mechanism. It was supposed to become the first new FDA-approved smoking cessation medication in 20 years this month — its PDUFA date was June 20. On June 22, the FDA issued a Complete Response Letter: manufacturing deficiencies, not clinical safety or efficacy concerns. Resubmission is planned for Q4 2026. The medication works. The pathway is delayed.

What new neuroimaging research is revealing is that nicotine’s effects go well beyond the dopamine pathway. A June 2026 study in Frontiers in Neuroscience using a novel MRI technique called CEST — Chemical Exchange Saturation Transfer, a way of measuring glutamate connectivity in the brain without radioactive tracers — found that nicotine simultaneously weakens cortico-hippocampal circuits (the networks that support memory and emotional processing) and strengthens thalamo-striatal circuits (the networks that drive habitual motor behaviors). In plain terms: nicotine quiets the reflective parts of your brain while it activates the parts that run on autopilot. You reach for a cigarette without thinking. That is not a metaphor. It is a description of what the drug does to your neural architecture.

In plain terms: nicotine quiets the reflective parts of your brain while it activates the parts that run on autopilot.

---

The historical gap: why tobacco got excluded from addiction treatment

For most of addiction medicine’s clinical history, tobacco was treated as a separate domain — a habit, not a disorder; a cancer problem, not an addiction problem. The American Society of Addiction Medicine didn’t formally address tobacco as a co-occurring substance use disorder in its treatment guidelines until the late 1990s. Treatment programs were reimbursed for addressing the substances that brought patients in the door. Nicotine was not that substance, and nobody was billing for it.

The cost of that exclusion has been enormous. People with SUD who smoke die earlier — not primarily from overdose, but from the cardiovascular disease, lung cancer, and COPD that accumulate over years of dual exposure. And we now know that smoking cessation during SUD treatment improves outcomes for the primary substance use disorder — a large cohort study covering 2013 to 2023 found that people who quit tobacco during SUD treatment were 30 percent more likely to achieve recovery from their primary substance use disorder at follow-up. The mechanisms are multiple: nicotine cessation normalizes dopamine signaling, improving the brain’s capacity for natural reward response; it reduces the cue-triggered craving activated by smoking; it may also, frankly, reflect the kind of sustained behavioral change that generalizes to other substance abstinence. The research doesn’t prove causality definitively, but the association is consistent and large.

Forty-two percent of SUD programs offering tobacco cessation services, when 80 percent of their patients use tobacco, is a significant gap. If your program is not offering it, that is a policy decision worth revisiting, not a resource gap you have to accept.

---

This week’s news: the FDA’s foreign manufacturer rule

On June 26, 2026 — yesterday — the FDA proposed a new rule requiring foreign tobacco product manufacturers to register with the agency, list their products sold in the United States, and submit detailed product information including nicotine concentrations and e-cigarette specifications. Foreign-made facilities would face FDA inspections before products enter the American market.

This closes a regulatory gap that has existed since the Family Smoking Prevention and Tobacco Control Act of 2009: domestic manufacturers faced these requirements; overseas producers did not. As the nicotine market has become increasingly global — and as oral nicotine pouches and disposable vapes manufactured abroad have surged — the gap between what domestic and foreign producers were required to disclose has grown. The FDA estimates roughly 53 percent of young daily vapers cannot quit, up from 28.2 percent in 2020. Products manufactured in facilities with no FDA inspection requirement are a meaningful part of what they cannot quit.

The rule is in public comment through September 14, 2026. It is not a ban on foreign products. It is the application of the same oversight that domestic manufacturers have been subject to for 17 years, extended to the global supply chain that has developed in the meantime.

---

If you’re in recovery and you still smoke

If you are, no one has told you anything you don’t already know. What they may not have told you is that quitting nicotine after quitting another substance is both harder and more important than most treatment programs let on. Your brain spent years building the same reward pathways that powered your primary use, and nicotine has been maintaining them. Quitting everything at once is hard. Quitting nicotine after you’ve stabilized on your primary substance is also hard, for different reasons. The 30 percent better recovery outcome is a population number, not a prescription.

What exists today that will help: cytisinicline is coming (Q4 resubmission, likely H1 2027 approval). Varenicline works and is available now. Nicotine replacement therapy (patches, gum, lozenge) reduces withdrawal without requiring abstinence as a first step. Combination therapy — patch plus a faster-acting form — consistently outperforms either alone. The EX Program at Truth Initiative combined with your own readiness has been shown in randomized trials to increase quit odds by up to 40 percent.

Combination therapy — patch plus a faster-acting form — consistently outperforms either alone.

You are not a smoker who also had a drug problem. You are a person with two overlapping neurobiological conditions that used the same brain hardware. Treating them as one story rather than two separate ones is not a moral position. It is a clinical description of what actually happened in your nervous system.